Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers (clinicaltrials.gov) - Oct 1, 2026 - P2 | N=50 | Terminated | Sponsor: Alaunos Therapeutics | Completed ➔ Terminated; Sponsor stopped enrollment at 50 of 70 planned patients because an activity signal had been observed in lymphoma and further enrollment would not add significantly to interpretation of efficacy or safety.
Trial termination • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|